CRISPR-Cas9 for Sickle-Cell Anaemia
~Preet The writer or publisher has no rights to this image. This image is taken from crisprcas9-genome-editing-technology-that-260nw-1121736050.jpg In 2021, India will launch a five-year initiative to produce Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to treat sickle cell anaemia. In India, sickle cell anaemia is the first illness targeted for CRISPR-based treatment. The pre-clinical phase (animal studies) is set to commence. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene editing system that uses a specific enzyme called Cas9 to mimic bacteria's natural defence mechanism against viral assaults. It generally entails the insertion of a new gene or the silencing of an existing gene via a process known as genetic engineering. CRISPR technique does not entail the insertion of any new genes from outside sources. CRISPR-Cas9 technology is frequently referred to as 'Genetic Scissors.' Its method is sometimes equated to the